EA020886B1 - Гуманизированные антитела против tl1a - Google Patents

Гуманизированные антитела против tl1a Download PDF

Info

Publication number
EA020886B1
EA020886B1 EA201070596A EA201070596A EA020886B1 EA 020886 B1 EA020886 B1 EA 020886B1 EA 201070596 A EA201070596 A EA 201070596A EA 201070596 A EA201070596 A EA 201070596A EA 020886 B1 EA020886 B1 EA 020886B1
Authority
EA
Eurasian Patent Office
Prior art keywords
zeg
tug
polypeptide
azr
azp
Prior art date
Application number
EA201070596A
Other languages
English (en)
Russian (ru)
Other versions
EA201070596A1 (ru
Inventor
Роджер СМИТ
Паланисами КАНАКАРАДЖ
Виктор РОШКЕ
Крейг РОУЗЕН
Бриджет А. Кукси
Original Assignee
ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. filed Critical ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК.
Publication of EA201070596A1 publication Critical patent/EA201070596A1/ru
Publication of EA020886B1 publication Critical patent/EA020886B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA201070596A 2007-11-13 2008-11-13 Гуманизированные антитела против tl1a EA020886B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98765107P 2007-11-13 2007-11-13
PCT/US2008/083362 WO2009064854A2 (en) 2007-11-13 2008-11-13 Humanized antibodies against tl1a

Publications (2)

Publication Number Publication Date
EA201070596A1 EA201070596A1 (ru) 2010-12-30
EA020886B1 true EA020886B1 (ru) 2015-02-27

Family

ID=40394148

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070596A EA020886B1 (ru) 2007-11-13 2008-11-13 Гуманизированные антитела против tl1a

Country Status (15)

Country Link
US (3) US8263743B2 (https=)
EP (2) EP2220122A2 (https=)
JP (1) JP5745854B2 (https=)
KR (1) KR101248422B1 (https=)
CN (1) CN101903402B (https=)
AU (1) AU2008320987B2 (https=)
BR (1) BRPI0819205A2 (https=)
CA (1) CA2705292C (https=)
EA (1) EA020886B1 (https=)
IL (1) IL205502A (https=)
MX (1) MX2010005282A (https=)
NZ (1) NZ585559A (https=)
UA (1) UA104132C2 (https=)
WO (1) WO2009064854A2 (https=)
ZA (1) ZA201003361B (https=)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
JP5781514B2 (ja) * 2009-09-06 2015-09-24 プロトエービー リミテッド Ｈｓｐ６５由来のペプチド６に特異的なヒト化抗体、その方法及び使用
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
JP2014511174A (ja) 2011-02-07 2014-05-15 ネオトープ バイオサイエンシーズ リミテッド Ａｐｏｅ免疫療法
EP2673297A2 (en) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
WO2012161856A1 (en) * 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
SG11201400916XA (en) 2011-08-22 2014-06-27 Cangene Corp Clostridium difficile antibodies
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
WO2014055967A2 (en) * 2012-10-05 2014-04-10 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
WO2014106602A1 (en) * 2013-01-02 2014-07-10 Glenmark Pharmaceuticals S.A. Antibodies that bind to tl1a and their uses
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
KR102042174B1 (ko) 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
TWI636065B (zh) * 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
US20160264684A1 (en) * 2013-10-10 2016-09-15 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9683998B2 (en) * 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
US10160805B2 (en) 2014-07-11 2018-12-25 New York University Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
DK3270965T3 (da) 2015-03-18 2020-06-08 Seattle Genetics Inc Cd48-antistoffer og konjugater deraf
US20170021020A1 (en) 2015-07-23 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibody and vaccine targeting filamentous bacteriophage
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
US20180319889A1 (en) * 2015-11-02 2018-11-08 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
EP3436480A4 (en) 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
MX392069B (es) * 2016-05-09 2025-03-21 Bristol Myers Squibb Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
EP3458466B1 (en) 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
JP2019534859A (ja) * 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
KR20190082815A (ko) * 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
SG11201909708VA (en) * 2017-04-21 2019-11-28 Mellitus Llc Methods and antibodies for diabetes-related applications
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CN112585165B8 (zh) * 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
RU2687609C1 (ru) * 2018-05-30 2019-05-15 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
NZ787680A (en) 2019-10-24 2026-02-27 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
BR112022013892A2 (pt) * 2020-01-13 2022-10-04 Truebinding Inc Anticorpos anti-gal3 e métodos de uso
WO2021202798A1 (en) * 2020-04-02 2021-10-07 The United States Of America As Represented By The Secretary Of The Navy Antigen binding proteins to class 5 etec adhesins
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2023141297A2 (en) * 2022-01-21 2023-07-27 Marengo Therapeutics, Inc. Multifunctional molecules comprising g6b binder and/or cd34 binder and uses thereof
AU2024273758A1 (en) 2023-05-17 2025-12-04 Genentech, Inc. Anti-tl1a antibody therapeutic methods
CN120399074B (zh) * 2023-06-02 2025-12-30 安徽金百奥生物科技有限公司 一种与人dr3胞外域高亲和力的纳米抗体
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
CN120530139A (zh) * 2023-12-29 2025-08-22 成都优洛生物科技有限公司 抗tl1a抗体或其抗原结合片段及应用
CN120424214A (zh) * 2024-02-05 2025-08-05 三生国健药业（上海）股份有限公司 一种抗tl1a抗体及其制备方法和用途
WO2025212534A1 (en) * 2024-04-05 2025-10-09 Board Of Regents, The University Of Texas System Monoclonal antibodies neutralizing marburg and ravn virus
CN119552252B (zh) * 2025-01-16 2025-11-25 华润生物医药有限公司 抗tl1a抗体及其制备方法和应用
CN120699151A (zh) * 2025-06-26 2025-09-26 国科大杭州高等研究院 一种tl1a抗体及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018571A2 (en) * 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
WO2006127900A2 (en) * 2005-05-25 2006-11-30 Biogen Idec Ma Inc. Tl1a in the treatment of disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US20020111325A1 (en) * 1997-11-03 2002-08-15 Human Genome Sciences, Inc. VEGI, an inhibitor of angiogenesis and tumor growth
WO2003039491A2 (en) 2001-11-09 2003-05-15 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018571A2 (en) * 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
WO2006127900A2 (en) * 2005-05-25 2006-11-30 Biogen Idec Ma Inc. Tl1a in the treatment of disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAMIAS GIORGOS ET AL.: "Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 171, no. 9, 1 November 2003 (2003-11-01), pages 4868-4874, XP002425310, ISSN: 0022-1767, the whole document *
YU Y. ET AL.: "Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 89, 1 January 2001 (2001-01-01), pages 1161-1167, XP002977779, ISSN: 0009-7330, the whole document *

Also Published As

Publication number Publication date
CN101903402A (zh) 2010-12-01
KR101248422B1 (ko) 2013-04-09
US20090280116A1 (en) 2009-11-12
EP2220122A2 (en) 2010-08-25
JP2011502522A (ja) 2011-01-27
IL205502A (en) 2016-03-31
AU2008320987A1 (en) 2009-05-22
US20120308480A1 (en) 2012-12-06
CA2705292C (en) 2016-06-21
ZA201003361B (en) 2011-02-23
IL205502A0 (en) 2010-12-30
BRPI0819205A2 (pt) 2015-06-23
EP2500362A2 (en) 2012-09-19
WO2009064854A3 (en) 2009-07-30
US20140315250A1 (en) 2014-10-23
KR20100097683A (ko) 2010-09-03
CN101903402B (zh) 2014-07-16
US9416185B2 (en) 2016-08-16
NZ585559A (en) 2012-11-30
EA201070596A1 (ru) 2010-12-30
JP5745854B2 (ja) 2015-07-08
CA2705292A1 (en) 2009-05-22
MX2010005282A (es) 2010-08-31
EP2500362A3 (en) 2012-10-24
AU2008320987B2 (en) 2014-04-17
US8728482B2 (en) 2014-05-20
WO2009064854A2 (en) 2009-05-22
UA104132C2 (en) 2014-01-10
US8263743B2 (en) 2012-09-11

Similar Documents

Publication Publication Date Title
EA020886B1 (ru) Гуманизированные антитела против tl1a
JP7737740B2 (ja) 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
US11261245B2 (en) Ultra-potent neutralization of GM-CSF by multispecific antibodies and uses thereof
US11267894B2 (en) BAFF selective binding compounds and related methods
ES2365606T3 (es) Anticuerpos contra gm-csf quiméricos.
JP5258578B2 (ja) アレルギー性疾患を処置するための胸腺間質性リンホポエチン受容体に対する抗体
CN106029697B (zh) 具有经修饰的ch2-ch3序列的犬抗体
KR20200080304A (ko) Cd137에 결합하는 단일 도메인 항체
JP7102670B2 (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
CN112409483A (zh) 抗pd-l1纳米抗体
JP2008044966A (ja) インターロイキン−２２に対する抗体およびその使用
JP2022541022A (ja) 抗ｔｉｇｉｔ抗体及びその適用
US20250122296A1 (en) Bispecific antibody and use thereof
EP4585617A1 (en) Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof
JP2025157225A (ja) 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
CN117820478B (zh) 纳米抗体的串联分子及其在疾病治疗中的用途
WO2023236991A1 (zh) 靶向her2，pd-l1和vegf的三特异性抗体
JP7770189B2 (ja) Ｇｐｎｍｂ及びｃｄ３に特異的に結合する二重特異性抗体並びにその使用
CN115181180B (zh) 抗人程序性死亡配体-1（pd-l1）的抗体及其应用
HK40110110A (zh) 具有经修饰的ch2-ch3序列的犬抗体
HK40033623B (zh) 结合pd-1的抗体

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM